The Listing expenses expected to be incurred by us in FY2023 are expected to record an increase compared to FY2022 and have a material adverse impact on our net profit for FY2023 and therefore our Group may record a decrease in net profit in FY2023 as compared with FY2022 principally attributable to the increase in Listing expenses.
Summary · 第 17 页
Based on our unaudited consolidated management account, our revenue recognised for the nine months ended 30 September 2023 amounted to approximately RMB161.9 million.
We expect to incur a significant increase in net loss for 2023 due to (i) increase in fair value losses on convertible redeemable preferred shares, (ii) the anticipated costs associated with increased research and development activities and (iii) expenses in connection with the Listing incurred in 2023.
Summary · 第 25 页
Our Directors confirm that up to the date of this prospectus, save as disclosed above, there has been no material adverse change in our financial, operational or trading positions or prospects since June 30, 2023, being the end of the period reported on as set out in the Accountants’ Report included in Appendix I to this prospectus.
while there was a decrease in our gold sales volume in the four months period by approximately 26.5%, as compared to the corresponding period in 2022 due to the decrease in gold production as a result of the decrease in gold grade
Summary · 第 17 页
our Group expects a decrease in forecasted profit in the year ending 31 December 2023 notwithstanding the forecasted increase in average gold spot price mainly due to (i) implementation of the mine optimisation plan in 2023 which led to the decrease of the gold grade of our Songjiagou Open-Pit Mine, a decrease in total sales volume and a decrease in gross profit margin; and (ii) the increase in Listing expenses.
Summary · 第 17 页
save for the recent developments as described above and the impact of the listing expenses on the financial performance of our Group for the year ending 31 December 2023, there has been no material adverse change in our financial or trading position, indebtedness, mortgage, contingent liabilities, guarantees or prospects since 30 June 2023, being the end date of the periods reported in the Accountant’s Report set out in Appendix I
泛远国际控股集团有限公司FAR International Holdings Group Company Limited02516.HK
FY2023服务售价预计下降
Our Directors confirmed that save for the estimated non-recurring Listing expenses as disclosed in the section headed “Financial Information — Listing expenses” in this prospectus and the estimated decrease in selling price of our Group’s services in FY2023 as disclosed in the paragraph headed “Recent development — Impact of COVID-19” in this section, since 30 June 2023 and up to the date of this prospectus, there has been no material adverse change in our financial or operating position or prospect or adverse event to the overall economic and market conditions in the industry where we operate which had materially affected our business, results or operations or the information shown in our consolidated financial information included in our Accountants’ Report in Appendix I to this prospectus.
Summary · 第 28 页
Our Directors confirmed that save for the estimated non-recurring listing expenses as disclosed in the paragraph headed “Listing Expenses” in this section and the estimated decrease in selling price of our Group’s services in FY2023 as disclosed in the paragraph headed “Summary — Recent development — Impact of COVID-19” in this prospectus, since 30 June 2023 and up to the date of this prospectus, there has been no material adverse change in our financial or operating position or prospect or adverse event to the overall economic and market conditions in the industry where we operate which had materially affected our business, results or operations or the information shown in our consolidated financial information included in our Accountants’ Report in Appendix I to this prospectus.
Based on our unaudited management accounts, our average monthly net profit for the four months ended 31 October 2023 experienced a decrease, as compared to that of the six months ended 30 June 2023, primarily due to a decrease in the average selling price of our LNG.
Summary · 第 8 页
We expect to record a significant decrease in profit for the year ending 31 December 2023, as compared to that for the year ended 31 December 2022, which is primarily due to the decrease in segment revenue of our energy products as a result of the decrease in the average selling price of LNG.
Summary · 第 9 页
The increase of the average selling price of our hydrogenated benzene-based chemicals and the decrease of the average selling price of our LNG are in line with their respective prevailing market price during the relevant periods.
We expect to incur net loss and increased net operating cash outflow in 2023.
Summary · 第 29 页
Despite that we expect a decline in revenue for 2023, we aim to maintain sustainability and achieve profitability in the future through: (i) continuously growing revenue and expanding sales volume; (ii) improving gross margin; and (iii) enhancing operating leverage.
Summary · 第 21 页
Our Directors confirm that, up to the date of this prospectus, there has been no material adverse change in our financial or trading position since June 30, 2023 (being the date on which the latest audited consolidated financial information of our Group was prepared) and there is no event since June 30, 2023 which would materially affect the information shown in our consolidated financial statements included in the Accountant’s Report set out in Appendix I to this prospectus.
Based on our unaudited management accounts, we recorded net loss in the third quarter of 2023, which was primarily due to the decrease in selling prices of our battery products as a result of the continuous decrease in prices of key raw materials such as lithium carbonate as mentioned-above, while our costs of raw materials did not decrease to the same extent as in the third quarter of 2023, we mainly used the raw materials in stock procured when the prices of raw materials were still at a relatively high level.
Summary · 第 30 页
We expect to record a substantial increase in net loss in 2023, primarily because (i) China’s EV market is yet to fully recover from the slowdown in early 2023 despite the gradual recovery in the second half of 2023, which adversely affect the sales volume of our EV battery products, (ii) we recorded losses in the first half of 2023, primarily because (a) the temporary slowdown in the EV industry in China in early 2023, directly affected the market demands for EVs, and (b) certain EV manufacturers did not place their orders for EV batteries in early 2023 because they expected the price of EV batteries to further decrease as the price of lithium carbonate decreased, and (iii) the intensified market competition in EV and ESS industries in China in the second half of 2023 is expected to have a negative impact on our gross profit margin.
Due to increase in our Listing expenses, we expect a decrease in the forecast profit for the year ending December 31, 2023.
Summary · 第 15 页
Our profit and total comprehensive income decreased from HK$32.5 million for the five months ended May 31, 2022 to HK$22.9 million for the five months ended May 31, 2023 as a result of the increase in Listing expenses and net expected credit losses due to increase in loan receivables, which has offset the increase in interest income as we gradually grow our loan portfolio.
升辉清洁集团控股有限公司Shenghui Cleanness Group Holdings Limited02521.HK
预期2023年度净利润下降
Our Directors consider that our projected net profit for the year ending 31 December 2023 is expected to record a decrease, compared to the net profit for the year ended 31 December 2022, which is affected by (i) an expected increase in general and administrative expenses and
Summary · 第 15 页
The expected increase in general and administrative expenses is primarily attributable to the expected increase in listing expenses, including underwriting commission in connection with the Share Offer.
Summary · 第 15 页
The expected increase in net impairment losses on financial assets is primarily attributable to our Group measures loss allowance for the trade receivables at an amount equal to lifetime expected credit loss and in view of the slowing economy in the PRC, for prudence’s sake, our Group expected to increase the provision of impairment loss on financial assets in FY2023.
For the eight months ending 31 December 2023, our Group expects to incur additional Listing expenses of RMB13.2 million (equivalent to HK$14.9 million) which will be charged to profit or loss.
Summary · 第 18 页
As a result of the expected increase in Listing expenses, our Group expects a decrease in forecast profit for the year ending 31 December 2023.
We recorded a net loss of RMB80.9 million for the three months ended March 31, 2023.
Summary · 第 3 页
We expect a decrease in net profit for the year ending December 31, 2023 as compared to the year ended December 31, 2022, primarily due to: (i) the decrease in fair value of certain listed and private portfolio companies in the first six months of 2023, and (ii) net impairment recognized under expected credit loss model of RMB28.3 million in the first six months of 2023, primarily attributable to loss allowance in relation to our deposits in Silicon Valley Bank, which are partially offset by (iii) the decrease in the interest on bond payables for the year ending December 31, 2023 as we redeemed the bond 17Tiantu01 and 17Tiantu02 upon maturity in 2022.
Summary · 第 41 页
Our Directors confirm that save as disclosed above, there has been no material adverse change in our business, financial condition and results of operations since March 31, 2023, being the latest balance sheet date of our consolidated financial statements as set out in the Historical Financial Information included in Appendix I to this prospectus, and up to the date of this prospectus.
We expect to record substantial amount of net losses for the year ending December 31, 2023, which is primarily due to our continued investments in research and development of our technologies and solutions, marketing initiatives, share-based compensation as well as estimated interest expense from redemption liabilities.
Summary · 第 30 页
Our Directors confirm that, as of the date of this Prospectus, there has been no material adverse change in our financial or trading position, indebtedness, mortgage, contingent liabilities, guarantees or prospects of our Group since March 31, 2023, the end of the period reported on in the Accountant’s Report included in Appendix I to this Prospectus.
We expect to incur net loss for the year ending December 31, 2023, because, despite the expected increase in revenue and gross profit, our gross profit generated was unable to compensate for our operating expenses, including selling and distribution expenses, research and development expenses and administrative expenses.
Summary · 第 27 页
Since April 1, 2023, we have witnessed growth in our business operations, including, but not limited to, increases in the service volumes of both the Internet medical services and health management services in the first seven months of 2023 compared to the same period in 2022.
For the three months ended March 31, 2023, we recorded total revenues of RMB768.0 million, a decline of 31.0% as compared to the same period in 2022, among which revenues generated from medical diagnostic testing services totaled RMB700.0 million, accounting for 91.1% of our total revenues, showing a decline of 31.7% compared to the same period in 2022.
Summary · 第 10 页
We expect our net profit for the year ending December 31, 2023 to decrease significantly compared to the year ended December 31, 2022, as a result of expected decline of revenues contributed by COVID-19 testing services in 2023.
Summary · 第 10 页
However, with the lift of COVID-19 restrictions, demand for our base testing services rebounded, which boosted our non-COVID revenue growth.
We expect that we will possibly continue to be loss-making in 2023 primarily due to the loss from the fair value change of financial liabilities at fair value through profit or loss and a large amount of selling and marketing expenses as we are still at the stage of rapid business expansion.
We expect to incur a significant increase in net loss for 2023 due to (i) the anticipated costs associated with increased research and development activities, (ii) fair value loss of financial liabilities at fair value through profit or loss, (iii) the anticipated increase in staff costs for administrative activities, and sales and marketing activities as we expand our business operations in 2023, and (iv) expenses in connection with the Listing incurred in 2023.
Summary · 第 30 页
Our Directors confirm that up to the date of this Prospectus, there has been no material adverse change in our financial, operational or trading positions or prospects since December 31, 2022, being the end of the period reported on as set out in the Accountants’ Report included in Appendix I to this Prospectus.
We experienced a decrease in NDRR and NDRR for pay-as-you-go office IT integrated solutions in 2022 primarily because although our customers largely maintained business relationship with us, growth in demands from our customers was moderated during the same year, primarily in relation to such customers' lowered rate of business growth or even downsized workforce.
Summary · 第 29 页
In 2023, we expect to record an increase in net losses due to (i) fair value changes of financial liabilities at FVTPL, representing non-cash expenses arising from granting preferred shares, warrants and convertible bonds to investors, and (ii) listing expenses.
Our net profit may experience a decrease for the year ending 31 December 2023 as compared to that of the year ended 31 December 2022, mainly due to (i) the expected Listing expenses to be incurred during the year; and (ii) the possible decrease in our other income as majority of our government grants received in FY2022 were non-recurring in nature and the timing, amounts and conditions of these government grants were within the sole discretion of the government, which we may not be able to receive those government grants at similar levels in 2023.
We expect that we will record net loss in 2023, primarily because we expect to continue to incur research and development expenses as we advance the development of our pipeline.
Summary · 第 28 页
In particular, we expect to complete the Phase II clinical trial for LZ901 in China in the second quarter of 2023, and initiate a Phase III clinical trial in the second quarter of 2023, which would expect to result in a significant increase in research and development expenses in 2023.